Stemline Therapeutics Inc (STML) CEO Ivan Bergstein Sold $515,697 of Shares

17 Aug 2019 - Yahoo News
CEO of Stemline Therapeutics Inc (30-Year Financial, Insider Trades) Ivan Bergstein (insider trades) sold 35,010 shares of STML on 08/14/2019 at an average price of $14.73 a share. Continue reading...
usx:stml

---

Should Stemline Therapeutics, Inc. (NASDAQ:STML) Be Your Next Stock Pick?

14 Aug 2019 - Yahoo News
Stemline Therapeutics, Inc. (NASDAQ:STML) is a company with exceptional fundamental characteristics. Upon building up...
usx:stml

---

Checking In on 2 Small Biotech Names That Had Big Quarters

12 Aug 2019 - Yahoo News
Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.
usx:stml

---

Stemline Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

9 Aug 2019 - Yahoo News
NEW YORK, Aug. 09, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.
usx:stml

---

Stemline Therapeutics Announces Pricing of $76,250,000 Public Offering of Common Stock

9 Aug 2019 - Yahoo News
NEW YORK, Aug. 08, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and.
usx:stml

---

Stemline Therapeutics Announces Proposed Public Offering of Common Stock

7 Aug 2019 - Yahoo News
NEW YORK, Aug. 07, 2019 -- Stemline Therapeutics, Inc. (Nasdaq:STML), a commercial -stage biopharmaceutical company focused on discovering, acquiring, developing and.
usx:stml

---

Stemline Therapeutics Announces that CMS Grants New Technology Add-on Payment (NTAP) to ELZONRIS®

6 Aug 2019 - Yahoo News
Stemline Therapeutics, Inc. (STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that the Centers for Medicare & Medicaid Services (CMS) granted approval for a new technology add-on payment (NTAP) for ELZONRIS ...
usx:stml

---

Edited Transcript of STML earnings conference call or presentation 2-Aug-19 12:00pm GMT

3 Aug 2019 - Yahoo News
Q2 2019 Stemline Therapeutics Inc Earnings Call
usx:stml

---

Stemline Therapeutics (STML) Reports Q2 Loss, Tops Revenue Estimates

2 Aug 2019 - Nasdaq
Stemline Therapeutics STML came out with a quarterly loss of 0 42 per share versus the Zacks Consensus Estimate of a loss of 0 47 This compares to loss of 0 66 per share a year ago These figures are adjusted for non recurring items This quarterly report represents an earnings surprise
usx:stml

---

Stemline Therapeutics Reports Second Quarter 2019 Financial Results

2 Aug 2019 - Yahoo News
Net revenue for ELZONRIS® was $13.0 million for the second quarterConference call and live webcast scheduled for today at 8:00 AM ET NEW YORK, Aug. 02, 2019 -- Stemline.
usx:stml

---